Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system

Cannon, 2015, Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, CD004816 Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol, 29, 151, 10.1016/j.cjca.2012.11.032 Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Teramoto, 2013, Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version, J Atheroscler Thromb, 20, 603, 10.5551/jat.15867 Gamboa, 2014, Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease, Am J Med Sci, 348, 108, 10.1097/MAJ.0000000000000292 Hoeks, 2009, Medication underuse during long-term follow-up in patients with peripheral arterial disease, Circ Cardiovasc Qual Outcomes, 2, 338, 10.1161/CIRCOUTCOMES.109.868505 Kern, 2014, Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III, Curr Med Res Opin, 30, 2443, 10.1185/03007995.2014.971151 Subherwal, 2012, Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains, Circulation, 126, 1345, 10.1161/CIRCULATIONAHA.112.108787 Bitzur, 2013, Intolerance to statins: mechanisms and management, Diabetes Care, 36, S325, 10.2337/dcS13-2038 Guyton, 2014, An assessment by the Statin Intolerance Panel: 2014 update, J Clin Lipidol, 8, S72, 10.1016/j.jacl.2014.03.002 Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study, Cardiovasc Drugs Ther, 19, 403, 10.1007/s10557-005-5686-z Buettner, 2008, Prevalence of musculoskeletal pain and statin use, J Gen Intern Med, 23, 1182, 10.1007/s11606-008-0636-7 Cohen, 2012, Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003 El-Salem, 2011, Prevalence and risk factors of muscle complications secondary to statins, Muscle Nerve, 44, 877, 10.1002/mus.22205 Nichols, 2007, Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients, Clin Ther, 29, 1761, 10.1016/j.clinthera.2007.08.022 Parker, 2013, Effect of statins on skeletal muscle function, Circulation, 127, 96, 10.1161/CIRCULATIONAHA.112.136101 Zhang, 2013, Discontinuation of statins in routine care settings: a cohort study, Ann Intern Med, 158, 526, 10.7326/0003-4819-158-7-201304020-00004 American College of Cardiology Statin Intolerance App [mobile application]. American College of Cardiology website http://www.acc.org/StatinIntoleranceApp. Accessed August 22, 2016. Banach, 2015, Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel, Arch Med Sci, 11, 1, 10.5114/aoms.2015.49807 Jacobson, 2014, NLA Task Force on Statin Safety–2014 update, J Clin Lipidol, 8, S1, 10.1016/j.jacl.2014.03.003 Mancini, 2016, Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016), The Can J Cardiol, 32, S35, 10.1016/j.cjca.2016.01.003 Rosenson, 2014, An assessment by the Statin Muscle Safety Task Force: 2014 update, J Clin Lipidol, 8, S58, 10.1016/j.jacl.2014.03.004 Sharrett, 2001, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 104, 1108, 10.1161/hc3501.095214 Classifications of diseases, functioning, and disability. Centers for Disease Control and Prevention website http://www.cdc.gov/nchs/icd/icd9cm.htm. Updated June 19, 2013. Accessed August 22, 2016. Rosenbaum, 1989, Optimal Matching for Observational Studies, J Amer Statist Assoc, 84, 1024, 10.1080/01621459.1989.10478868 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Mampuya, 2013, Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience, Am Heart J, 166, 597, 10.1016/j.ahj.2013.06.004 Backes, 2008, Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance, Ann Pharmacother, 42, 341, 10.1345/aph.1K604 Juszczyk, 2005, Decreasing LDL cholesterol and medication cost with every-other-day statin therapy, Prev Cardiol, 8, 197, 10.1111/j.0197-3118.2005.04404.x Jacobson, 2015, National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report, J Clin Lipidol, 9, 129, 10.1016/j.jacl.2015.02.003 Rodriguez, 2015, Frequency of high-risk patients not receiving high-potency statin (from a large managed care database), Am J Cardiol, 115, 190, 10.1016/j.amjcard.2014.10.021 Chi, 2014, Adherence to statins and LDL-cholesterol goal attainment, Am J Manag Care, 20, e105 Wong, 2016, Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012, J Clin Lipidol, 10, 1109, 10.1016/j.jacl.2016.06.011 Tattersall, 2013, Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys, PLoS One, 8, e59309, 10.1371/journal.pone.0059309 Daskalopoulou, 2008, Discontinuation of statin therapy following an acute myocardial infarction: a population-based study, Eur Heart J, 29, 2083, 10.1093/eurheartj/ehn346 Gomez Sandoval, 2011, Statin discontinuation in high-risk patients: a systematic review of the evidence, Curr Pharm Des, 17, 3669, 10.2174/138161211798220891 Rasmussen, 2007, Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction, JAMA, 297, 177, 10.1001/jama.297.2.177 Tziomalos, 2008, Statin discontinuation: an underestimated risk [editorial]?, Curr Med Res Opin, 24, 3059, 10.1185/03007990802469102 Bozovich, 2000, Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals, Pharmacotherapy, 20, 1375, 10.1592/phco.20.17.1375.34895 Mazzolini, 2005, Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers, J Manag Care Pharm, 11, 763, 10.18553/jmcp.2005.11.9.763 Gavish, 2002, Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients, Isr Med Assoc J, 4, 694 Slinin, 2012, Association of provider-patient visit frequency and patient outcomes on hemodialysis, J Am Soc Nephrol, 23, 1560, 10.1681/ASN.2012010051 Shin, 2014, Impact of continuity of care on mortality and health care costs: a nationwide cohort study in Korea, Ann Fam Med, 12, 534, 10.1370/afm.1685 Cho, 2015, The Association between Continuity of Care and All-Cause Mortality in Patients with Newly Diagnosed Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study, 2005-2012, PLoS One, 10, e0141465, 10.1371/journal.pone.0141465 Lin, 2016, Patterns of statin use in a real-world population of patients at high cardiovascular risk, J Manag Care Spec Pharm, 22, 685, 10.18553/jmcp.2016.22.6.685 Jacobson, 2016, Development and content validation of a patient-reported outcome measure to evaluate statin intolerance in the real world, Value Health, 19, A52, 10.1016/j.jval.2016.03.173 Ahmad, 2014, Statin intolerance, Am J Cardiol, 113, 1765, 10.1016/j.amjcard.2014.02.033